Latest survival data from three Phase II ipilimumab studies showed almost half of previously treated metastatic melanoma patients alive beyond one year1,2,3
- Data presented at the 33rd Congress of the European Society for Medical Oncology -
Stockholm – 16 September 2008 – Bristol-Myers Squibb announced updated survival data from three Phase II studies of ipilimumab in patients with advanced metastatic melanoma (Stage III or IV), which showed that approximately half of previously-treated patients who received ipilimumab (10 mg/kg) remained alive beyond one year. 1,2,3 Ipilimumab is designed to block the activity of CTLA-4 (a molecule on T-cells that plays a critical role in regulating natural immune responses), and thereby activates the immune system to fight metastatic melanoma.4,5
The results are based on a follow-up of the patient population from studies 008, 022 and 007. 47 – 51 percent of patients with advanced metastatic melanoma treated with 10 mg/kg of ipilimumab (induction and maintenance) showed a consistent survival rate of one-year.1,2,3 Specifically, the results show:
* 47 percent of patients who had progressed while on or after receiving standard treatment achieved one year survival (Study 008)1
* 48 percent of patients who were previously treated, relapsed or failed to respond to experimental treatment or were unable to tolerate currently approved therapies achieved one-year survival (Study 022)2
* 51 percent of patients previously treated with therapy other than ipilimumab achieved one year survival (Study 007)3
Recent medical literature, based on a meta-analysis of 42 Phase II trials with 2,100 patients, reported a one-year survival rate of approximately 25.5 percent for patients with Stage III or IV metastatic melanoma, the most advanced type of the disease.6
http://www.countrydoctor.co.uk/education/Education%20-%20Metastatic%20melanoma%20hopes.htm
Jimmy B
No comments:
Post a Comment